# A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

> **NCT03957681** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Moderate to Severe Systemic Sclerosis

## Interventions

- **DRUG:** KHK4827
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03957681
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-23
- **Primary completion:** 2020-10-16
- **Final completion:** 2025-04-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957681, "A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03957681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*